JP7720787B2 - 核酸のランダム化された構成標的化組込み - Google Patents

核酸のランダム化された構成標的化組込み

Info

Publication number
JP7720787B2
JP7720787B2 JP2021576250A JP2021576250A JP7720787B2 JP 7720787 B2 JP7720787 B2 JP 7720787B2 JP 2021576250 A JP2021576250 A JP 2021576250A JP 2021576250 A JP2021576250 A JP 2021576250A JP 7720787 B2 JP7720787 B2 JP 7720787B2
Authority
JP
Japan
Prior art keywords
host cells
sois
sequence
certain embodiments
library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576250A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020264253A5 (https=
JP2022538073A (ja
JP2022538073A5 (https=
Inventor
シャーラム ミサギ，
ブラッドリー アール． スネデカー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2022538073A publication Critical patent/JP2022538073A/ja
Publication of JPWO2020264253A5 publication Critical patent/JPWO2020264253A5/ja
Publication of JP2022538073A5 publication Critical patent/JP2022538073A5/ja
Priority to JP2025073331A priority Critical patent/JP2025121945A/ja
Application granted granted Critical
Publication of JP7720787B2 publication Critical patent/JP7720787B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021576250A 2019-06-26 2020-06-26 核酸のランダム化された構成標的化組込み Active JP7720787B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025073331A JP2025121945A (ja) 2019-06-26 2025-04-25 核酸のランダム化された構成標的化組込み

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962866893P 2019-06-26 2019-06-26
US62/866,893 2019-06-26
US202062991708P 2020-03-19 2020-03-19
US62/991,708 2020-03-19
PCT/US2020/039753 WO2020264253A1 (en) 2019-06-26 2020-06-26 Randomized configuration targeted integration of nucleic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025073331A Division JP2025121945A (ja) 2019-06-26 2025-04-25 核酸のランダム化された構成標的化組込み

Publications (4)

Publication Number Publication Date
JP2022538073A JP2022538073A (ja) 2022-08-31
JPWO2020264253A5 JPWO2020264253A5 (https=) 2023-07-04
JP2022538073A5 JP2022538073A5 (https=) 2023-07-04
JP7720787B2 true JP7720787B2 (ja) 2025-08-08

Family

ID=71728890

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576250A Active JP7720787B2 (ja) 2019-06-26 2020-06-26 核酸のランダム化された構成標的化組込み
JP2025073331A Pending JP2025121945A (ja) 2019-06-26 2025-04-25 核酸のランダム化された構成標的化組込み

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025073331A Pending JP2025121945A (ja) 2019-06-26 2025-04-25 核酸のランダム化された構成標的化組込み

Country Status (11)

Country Link
US (2) US11634836B2 (https=)
EP (1) EP3990649A1 (https=)
JP (2) JP7720787B2 (https=)
KR (1) KR20220025806A (https=)
CN (1) CN114080454A (https=)
AU (1) AU2020308002A1 (https=)
CA (1) CA3141233A1 (https=)
IL (1) IL289146A (https=)
MX (1) MX2021015698A (https=)
TW (1) TWI891643B (https=)
WO (1) WO2020264253A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021262798A1 (en) * 2020-06-24 2021-12-30 Genentech, Inc. Targeted integration of nucleic acids
CN117305334B (zh) * 2022-06-21 2024-11-08 深圳太力生物技术有限责任公司 靶向整合细胞及其制备方法、生产目标基因表达产物的方法
JP2026502534A (ja) * 2023-01-12 2026-01-23 ジェネンテック， インコーポレイテッド 核酸の標的組込みのためのコンビナトリアルベクターのクローニングおよびトランスフェクション戦略
CN116466074B (zh) * 2023-03-20 2026-02-24 吉林大学 基于特异性抗原fhh的肝片吸虫胶体金检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523084A (ja) 2013-06-19 2016-08-08 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ 標的組込み
JP2017518362A (ja) 2014-05-02 2017-07-06 イオンタス リミテッド 真核細胞において発現されるタンパク質変異体のライブラリーの調製、及び結合性分子の選択に向けた使用
WO2017184832A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
WO2017184831A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
JP2018201520A (ja) 2012-11-30 2018-12-27 ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーＬａｒｉｘ Ｂｉｏｓｃｉｅｎｃｅ， Ｌｌｃ 新規な細胞株スクリーニング方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US7126041B1 (en) * 1999-12-10 2006-10-24 North Carolina State Unversity High efficiency gene targeting in plants
WO2008106985A1 (en) * 2007-03-07 2008-09-12 Aarhus Universitet Pig model
FR2927089B1 (fr) * 2008-02-05 2011-03-25 Inst Nat De La Rech Agronomique Inra Procede d'integration ciblee de multicopies d'un gene d'interet dans une souche de yarrowia
US9932607B2 (en) * 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
KR102243243B1 (ko) 2014-10-23 2021-04-22 리제너론 파마슈티칼스 인코포레이티드 신규한 cho 통합 부위 및 이의 용도
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018201520A (ja) 2012-11-30 2018-12-27 ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーＬａｒｉｘ Ｂｉｏｓｃｉｅｎｃｅ， Ｌｌｃ 新規な細胞株スクリーニング方法
JP2016523084A (ja) 2013-06-19 2016-08-08 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ 標的組込み
JP2017518362A (ja) 2014-05-02 2017-07-06 イオンタス リミテッド 真核細胞において発現されるタンパク質変異体のライブラリーの調製、及び結合性分子の選択に向けた使用
WO2017184832A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
WO2017184831A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus

Also Published As

Publication number Publication date
WO2020264253A1 (en) 2020-12-30
JP2025121945A (ja) 2025-08-20
US20230279583A1 (en) 2023-09-07
KR20220025806A (ko) 2022-03-03
JP2022538073A (ja) 2022-08-31
IL289146A (en) 2022-02-01
AU2020308002A1 (en) 2022-01-20
TW202115252A (zh) 2021-04-16
US11634836B2 (en) 2023-04-25
CN114080454A (zh) 2022-02-22
US20220119985A1 (en) 2022-04-21
MX2021015698A (es) 2022-03-17
TWI891643B (zh) 2025-08-01
CA3141233A1 (en) 2020-12-30
EP3990649A1 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
US20230049767A1 (en) Expression vector production and high-throughput cell screening
JP7720787B2 (ja) 核酸のランダム化された構成標的化組込み
US20220170049A1 (en) Method for the generation of a protein expressing cell by targeted integration using cre mrna
AU2020296247A1 (en) Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
US20220169731A1 (en) Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
US20220169730A1 (en) Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CN114258403B (zh) 通过以限定的组织形式靶向整合多个表达盒来产生多价多特异性抗体表达细胞的方法
US20240409615A1 (en) Multi-vector recombinase mediated cassette exchange
HK40109435A (zh) 通过使用cre mrna进行的靶向整合来产生蛋白质表达细胞的方法
HK40060851B (zh) 通过使用cre mrna进行的靶向整合来产生蛋白质表达细胞的方法
HK40041212A (en) Targeted integration of nucleic acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250729

R150 Certificate of patent or registration of utility model

Ref document number: 7720787

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150